MAIA Biotechnology, Inc., a clinical-stage biopharmaceutical company, has announced positive results from its Phase 2 THIO-101 clinical trial. The trial evaluated the efficacy of their lead clinical candidate, ateganosine (THIO), in combination with Regeneron's immune checkpoint inhibitor cemiplimab (Libtayo®) for patients with advanced non-small cell lung cancer (NSCLC) resistant to prior therapies. The latest data reveals a median overall survival $(OS)$ of 17.8 months for patients receiving at least one dose of ateganosine, significantly outperforming the typical 5 to 6 months OS seen in standard-of-care chemotherapy for similar cases. These findings suggest that ateganosine may considerably impact the NSCLC treatment landscape, with potential for accelerated FDA approval and exclusivity. The treatment has been generally well-tolerated in this heavily pre-treated patient population.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。